# A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct04077099/  
OnCo record `nct04077099` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of REGN5093 in non-small-cell lung cancer, run by Regeneron Pharmaceuticals, active and no longer recruiting.

## Summary

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT04077099 by Regeneron Pharmaceuticals, with 95 participants enrolled, started 2020-01-07 and due to reach its primary completion in 2027-07-06. Interventions recorded: REGN5093.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04077099
- Phase: 1/2
- Setting: A Phase 1/2 Study of REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer
- Sponsor: Regeneron Pharmaceuticals
- Enrolled: 95

## Sources

- ClinicalTrials.gov NCT04077099: https://clinicaltrials.gov/study/NCT04077099

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)

---
JSON: https://onco.cc/api/v1/entities/nct04077099.json